Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Pfizer Inc 66 HUDSON BOULEVARD EAST NEW YORK NY 10001 USA

www.pfizer.com Employees: 81,000 P: 212-733-2323

Sector:

Medical

Description:

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.'The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

Key Statistics

Overview:

Market Capitalization, $K 142,654,416
Enterprise Value, $K 205,962,416
Shares Outstanding, K 5,685,708
Annual Sales, $ 63,627 M
Annual Net Income, $ 8,031 M
Last Quarter Sales, $ 16,654 M
Last Quarter Net Income, $ 3,541 M
EBIT, $ 18,723 M
EBITDA, $ 25,736 M
60-Month Beta 0.46
% of Insider Shareholders 0.06%
% of Institutional Shareholders 68.36%
Float, K 5,682,297
% Float 99.94%
Short Interest 139,486
Short Float 2.45%
Short Volume Ratio 0.39

Growth:

1-Year Return -5.82%
3-Year Return -51.03%
5-Year Return -31.84%
5-Year Revenue Growth 22.95%
5-Year Earnings Growth 5.42%
5-Year Dividend Growth 16.67%

Per-Share Information:

Most Recent Earnings 0.87 on 11/04/25
Next Earnings Date 02/03/26
Earnings Per Share ttm 3.20
EPS Growth vs. Prev Qtr 11.54%
EPS Growth vs. Prev Year -17.92%
Annual Dividend & Yield 1.72 (6.86%)
Annual Dividend & Yield (Fwd) 1.72 (6.87%)
Most Recent Dividend 0.430 on 11/07/25
Next Ex-Dividends Date 01/23/26
Dividend Payable Date 03/06/26
Dividend Payout Ratio 53.31%
Most Recent Split 3-1 on 07/01/99

PFE Ratios

Ratio
Price/Earnings ttm 7.82
Price/Earnings forward 8.02
Price/Earnings to Growth N/A
Return-on-Equity % 20.17%
Return-on-Assets % 8.71%
Profit Margin % 12.62%
Debt/Equity 0.66
Price/Sales 2.24
Price/Cash Flow 5.74
Price/Book 1.53
Book Value/Share 16.37
Interest Coverage -1.47

PFE Dividends

Date Value
11/07/25 $0.4300
07/25/25 $0.4300
05/09/25 $0.4300
01/24/25 $0.4300
11/08/24 $0.4200
07/26/24 $0.4200
05/09/24 $0.4200
01/25/24 $0.4200
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar